BACKGROUND: Advances in intracranial stereotactic radiosurgery (SRS) have led to dramatically reduced planning target volume (PTV) margins. However, tumor growth between planning and treatment may lead to treatment failure. Our purpose was to assess the kinetics of tumor growth before SRS for brain metastases. METHODS: This retrospective, monocentric study included all consecutive patients (pts) treated for brain metastases secondary to melanoma (ML) and non-small cell lung cancer (NSCLC) between June 2015 and May 2016. All pts underwent diagnostic brain imaging and a radiosurgery planning MRI, during which gross tumor volume (GTV) was delineated. Linear and exponential models were used to extrapolate a theoretical GTV at first day of treatment, and theoretical time to outgrow the PTV margins. RESULTS: Twenty-three ML and 31 NSCLC brain metastases (42 pts, 84 brain imaging scans) were analyzed. Comparison of GTV at diagnosis and planning showed increased tumor volume for 20 ML pts (96%) and 22 NSCLC pts (71%). The shortest time to outgrow a 1 mm margin was 6 days and 3 days for ML and 14 and 8 days for NSCLC with linear and exponential models, respectively. CONCLUSIONS: Physicians should bear in mind the interval between SRS planning and treatment. A mathematical model could screen rapidly progressing tumors.
BACKGROUND: Advances in intracranial stereotactic radiosurgery (SRS) have led to dramatically reduced planning target volume (PTV) margins. However, tumor growth between planning and treatment may lead to treatment failure. Our purpose was to assess the kinetics of tumor growth before SRS for brain metastases. METHODS: This retrospective, monocentric study included all consecutive patients (pts) treated for brain metastases secondary to melanoma (ML) and non-small cell lung cancer (NSCLC) between June 2015 and May 2016. All pts underwent diagnostic brain imaging and a radiosurgery planning MRI, during which gross tumor volume (GTV) was delineated. Linear and exponential models were used to extrapolate a theoretical GTV at first day of treatment, and theoretical time to outgrow the PTV margins. RESULTS: Twenty-three ML and 31 NSCLC brain metastases (42 pts, 84 brain imaging scans) were analyzed. Comparison of GTV at diagnosis and planning showed increased tumor volume for 20 ML pts (96%) and 22 NSCLC pts (71%). The shortest time to outgrow a 1 mm margin was 6 days and 3 days for ML and 14 and 8 days for NSCLC with linear and exponential models, respectively. CONCLUSIONS: Physicians should bear in mind the interval between SRS planning and treatment. A mathematical model could screen rapidly progressing tumors.
Authors: Zachary A Seymour; Shannon E Fogh; Sarah K Westcott; Steve Braunstein; David A Larson; Igor J Barani; Jean Nakamura; Penny K Sneed Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-07 Impact factor: 7.038
Authors: Jacob A Miller; Elizabeth E Bennett; Roy Xiao; Rupesh Kotecha; Samuel T Chao; Michael A Vogelbaum; Gene H Barnett; Lilyana Angelov; Erin S Murphy; Jennifer S Yu; Manmeet S Ahluwalia; John H Suh; Alireza M Mohammadi Journal: Int J Radiat Oncol Biol Phys Date: 2016-09-01 Impact factor: 7.038
Authors: Jaap D Zindler; George Rodrigues; Cornelis J A Haasbeek; Patricia F De Haan; Otto W M Meijer; Ben J Slotman; Frank J Lagerwaard Journal: Radiother Oncol Date: 2013-03-20 Impact factor: 6.280
Authors: Georges Noël; Jean Marc Simon; Charles Ambroise Valery; Philippe Cornu; Gilbert Boisserie; Dominique Hasboun; Dominique Ledu; Bernadette Tep; Jean Yves Delattre; Claude Marsault; François Baillet; Jean Jacques Mazeron Journal: Radiother Oncol Date: 2003-07 Impact factor: 6.280
Authors: Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger Journal: Pigment Cell Melanoma Res Date: 2016-10-22 Impact factor: 4.693
Authors: Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger Journal: Lancet Oncol Date: 2016-06-03 Impact factor: 41.316
Authors: J Lee Villano; Eric B Durbin; Chris Normandeau; Jigisha P Thakkar; Valentina Moirangthem; Faith G Davis Journal: Neuro Oncol Date: 2014-06-02 Impact factor: 12.300
Authors: Tugce Kutuk; Ranjini Tolakanahalli; Andre Williams; Martin C Tom; Jason D Vadhan; Haley Appel; Matthew D Hall; D Jay J Wieczorek; Stephen Davis; Michael W McDermott; Manmeet S Ahluwalia; Minesh P Mehta; Alonso N Gutierrez; Rupesh Kotecha Journal: Neurooncol Pract Date: 2021-07-28